Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label isavuconazole study in invasive aspergillosis with renal impairment or rare invasive fungal disease
2006-005003-33Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of isavuconazole in invasive aspergillosis (IA) and invasive mycoses (2 arms), sponsored by Astellas Pharma. Primary endpoint: Overall outcome of treatment evaluated by Data Review Committee. Started Nov 2007; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)invasive mycoses
Beyond the preview
Go deeper on 2006-005003-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005003-33.